President & CEO, Lycera
Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd. Prior to joining, Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009, Paul was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Paul was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
Previously, Paul spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Paul also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development – a department he established to ensure the differential competitive advantage of Novartis’ pipeline. Paul completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his B.S. in Zoology.
Paul has been a Director on more than 16 private and public company Boards, and is currently a member of the Board of Directors of Veeva Systems Inc., Pharming N.V., Enumeral Biomedical Holdings, Inc., Nuvelution Pharma, Inc. and Nivalis Therapeutics, Inc.
Additionally, he serves on several non-profit Boards including the BioExec Institute, Inc., the TB Alliance, Young Concert Artists, Inc., and the Caramoor Center for Music and the Arts. Paul also served as a Member of the Board of Trustees of Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.